THE BUSINESS
We see a competitive advantage in “bridging the gap” between the current nutraceutical and pharmaceutical world and the emerging world of cannabis and psychotropic compounds. By focusing on our “parallel” plant-based, biotech business development, and investment growth strategy Zephyr will grow unencumbered by any legal or regulatory issues faced by a singular cannabis focus.
COSMECEUTICALS
With the growing enthusiasm for medical beauty, and the cosmeceutical products serving this trend, Zephyr Labz ensures to offer our customers the best skin care ingredients and exciting options for a variety of skin care solutions.
Using advanced, clinically proven ingredients for personal care and by boosting the body’s natural defense and repair mechanisms, our products help users retain and regain their natural beauty in a safe and sustainable way. These products are designed to improve the long-term health of skin by reducing inflammation and other sources of aging, as well as promote quick healing for wounds and post-surgical and aesthetic procedures.
Our formulators use techniques developed over decades of research to manufacture specialty bio-identical proteins that push the leading edge of skin care technology. Other proprietary ingredients engage cellular activity to refresh dermal layers and help speed healing of the skin – after aesthetic procedures, and to more severe cases, such as wounds, burns, lesions and even diabetic ulcers.
As part of this work, we have also integrated CBD into a number of our products. In combination, these products are the most advanced and effective CBD containing products in the world.
NUTRACEUTICALS
According to Research and Markets, the global nutraceuticals market grew from $372.27 billion in 2022 to $409.12 billion in 2023 at a compound annual growth rate (CAGR) of 9.9%. This rapid growth is being driven by consumers in markets across the world taking more responsibility for their wellbeing and educating themselves about healthy living.
By leveraging our in-house manufactured brands and domestic and international distribution channels to expand market reach, Zephyr Labz plans to lead the industry with new concepts for innovative plant-based nutraceutical products and next generation delivery technologies that will benefit our customers today and tomorrow.
To drive Zephyr Labz’s expansion and planned growth in the nutraceutical consumer market, we are developing both proprietary and differentiated products in growing market segments such as “gummies”. In addition, we are acquiring other brands through a strategic buy-and-build strategy with the objective of creating a major international nutraceutical company promoting healthy aging around the world.
CANNACEUTICALS
The science behind non-psychotropic phytocannabinoids such as cannabidiol (CBD) is growing rapidly – a new and exciting field of research with promising findings in a wide variety of health areas including genetics, central nervous system (CNS) diseases, pain disorders, cancer and more. This is creating a myriad of opportunities to expand treatment strategies and support global patient health through the development of bespoke CBD-based drug products.
Zephyr Labz has developed a platform that facilitates early-stage product development and potentially novel scientific discoveries to benefit our customers health and lifestyle needs.
PHARMACEUTICAL
The inherent polypharmaceutical properties of cannabis botanicals offer distinct advantages over the current single-target pharmaceutical model and portend to revolutionize neurological treatment into a new reality of effective interventional and even preventative treatment.
Zephyr Labz has identified intriguing promise demonstrated by recent discoveries regarding the benefits of cannabis-based medicines to neurological therapeutics by incorporating the neutral phytocannabinoids tetrahydrocannabinol (THC), cannabidiol (CBD), their acidic precursors, tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA), and cannabis terpenoids in the putative treatment of several serious health conditions.
In addition, Zephyr Labz will be working closely with a DNA testing company to develop therapeutic products to address health concerns based on identified genetic test indications. The DNA test maps each user’s endocannabinoid system and matches the results with a specific cannabinoid ratio and terpene profile aligned with their genotype. Our team of research scientists developed a protocol to align distinctive markers found in the genetic test results with products to help consumers treat or offset a variety of health conditions. Genetic tests like these are being used in diagnosing mental conditions, including depression, PTSD, anxiety, OCD, and even more.
